Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESGO 2021 | Improving immunotherapy outcomes in ovarian cancer

Eric Pujade-Lauraine • 24 Oct 2021
ESGO 2021
Gynecological Cancer Ovarian Cancer Bevacizumab

Eric Pujade-Lauraine, MD, PhD, Hôpital Hôtel-Dieu, Paris, France, outlines approaches to improve outcomes in patients with ovarian cancer treated with immune checkpoint inhibitors, including combinations with chemotherapy as well as bevacizumab. This interview took place at the European Society of Gynaecological Oncology (ESGO) 2021 congress in Prague.

More from Eric Pujade-Lauraine

3:37
Selecting patients to be treated with maintenance olaparib in the PAOLA-1 trial
Eric Pujade-Lauraine • 20 Feb 2023
0:48
Immune checkpoint inhibitors in ovarian cancer
Eric Pujade-Lauraine • 24 Oct 2021
3:06
Results from the JAVELIN Ovarian 200 biomarker analysis
Eric Pujade-Lauraine • 24 Oct 2021
2:50
AURELIA: Phase 3 trial of bevacizumab combined with chemotherapy for ovarian cancer
Eric Pujade-Lauraine • 26 Sep 2015

Related Videos

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
0:46
FRa expression and sequencing ADCs in endometrial cancer
Rebecca Porter • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:11
Clonal hematopoiesis mutations in ovarian carcinomas
Rebecca Porter • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals